Actively Recruiting
A Study of TXN10128 in Subjects With Solid Tumors
Led by Txinno Bioscience Inc. · Updated on 2025-04-24
96
Participants Needed
6
Research Sites
152 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a phase I clinical trial to primarily evaluate the safety, tolerability, and addtionally assess pharmacokinetics, pharmacodynamics, and antitumor activity of investigational product, TXN10128. The target subjects will be consisted of patients with locally advanced (unresectable) or metastatic soild tumors. This study includes a dose-escalation part and a dose-expansion part, and a TXN10128 monotherapy part and a TXN10128 + Irinotecan or Paclitaxel combination therapy part.
CONDITIONS
Official Title
A Study of TXN10128 in Subjects With Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female subjects 19 years of age or older at the time of informed consent
- Histologically and/or cytologically confirmed progressive, locally advanced (unresectable), or metastatic solid tumors
- Tumors relapsed or refractory after last treatment or no standard therapy exists or is appropriate
- ECOG performance status of 0 or 1
- Life expectancy of at least 12 weeks
You will not qualify if you...
- Presence of leptomeningeal disease
- Experienced Grade 3 or higher immune-related adverse events with prior immunotherapy except non-clinically significant lab abnormalities
- Prior organ transplantation
- Known positive HIV infection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea, 13620
Actively Recruiting
2
Chungbuk National University Hospital
Cheonju, North Chungcheong, South Korea, 28644
Actively Recruiting
3
Seoul National Univ. Hospital
Seoul, Seoul, South Korea, 03080
Actively Recruiting
4
Asan Medical Center
Seoul, Seoul, South Korea, 05505
Actively Recruiting
5
Gachon University Gil Medical Center
Incheon, South Korea, 21565
Actively Recruiting
6
SAMSUNG Medical Center
Seoul, South Korea, 06351
Actively Recruiting
Research Team
E
Eun-Young Kwak, Ph.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here